NHS National Generic Pharmaceuticals- Lenalidomide
Offer reference number: CM/PHG/21/5638
Period of framework agreement: 01/09/2022 to 31/08/2023 (12 months) with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 48 months.
Potential periods of call-offs under the framework agreement:
Lenalidomide:
ALL REGIONS: 01/09/2022 to 31/08/2023 (12 months)

You must be logged in to view the rest of this content, click here to login

Don't have an account, click to sign up for our 14-day free trial.